X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA GLENMARK PHARMA ALEMBIC PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 29.5 12.0 246.0% View Chart
P/BV x 6.7 3.2 212.5% View Chart
Dividend Yield % 0.7 0.4 183.6%  

Financials

 ALEMBIC PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
GLENMARK PHARMA
Mar-17
ALEMBIC PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs792993 79.7%   
Low Rs443729 60.7%   
Sales per share (Unadj.) Rs167.0325.5 51.3%  
Earnings per share (Unadj.) Rs38.239.3 97.1%  
Cash flow per share (Unadj.) Rs42.048.7 86.3%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.60.2 279.0%  
Book value per share (Unadj.) Rs84.9159.2 53.3%  
Shares outstanding (eoy) m188.52282.17 66.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.72.6 139.7%   
Avg P/E ratio x16.221.9 73.8%  
P/CF ratio (eoy) x14.717.7 83.1%  
Price / Book Value ratio x7.35.4 134.4%  
Dividend payout %10.55.1 205.9%   
Avg Mkt Cap Rs m116,383242,991 47.9%   
No. of employees `000NA13.0 0.0%   
Total wages/salary Rs m4,21416,408 25.7%   
Avg. sales/employee Rs ThNM7,083.9-  
Avg. wages/employee Rs ThNM1,265.4-  
Avg. net profit/employee Rs ThNM855.1-  
INCOME DATA
Net Sales Rs m31,48791,857 34.3%  
Other income Rs m55374 14.7%   
Total revenues Rs m31,54292,230 34.2%   
Gross profit Rs m10,06020,367 49.4%  
Depreciation Rs m7222,644 27.3%   
Interest Rs m372,373 1.6%   
Profit before tax Rs m9,35615,724 59.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m2,1603,827 56.4%   
Profit after tax Rs m7,19411,088 64.9%  
Gross profit margin %31.922.2 144.1%  
Effective tax rate %23.124.3 94.9%   
Net profit margin %22.812.1 189.3%  
BALANCE SHEET DATA
Current assets Rs m15,06668,746 21.9%   
Current liabilities Rs m7,67427,027 28.4%   
Net working cap to sales %23.545.4 51.7%  
Current ratio x2.02.5 77.2%  
Inventory Days Days6785 78.8%  
Debtors Days Days4196 42.5%  
Net fixed assets Rs m8,23724,132 34.1%   
Share capital Rs m377282 133.6%   
"Free" reserves Rs m15,41644,643 34.5%   
Net worth Rs m16,00544,925 35.6%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m24,594117,639 20.9%  
Interest coverage x255.27.6 3,347.1%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.30.8 164.0%   
Return on assets %29.411.4 257.0%  
Return on equity %44.924.7 182.1%  
Return on capital %58.719.1 306.5%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,81156,152 31.7%   
Fx outflow Rs m5,3188,084 65.8%   
Net fx Rs m12,49348,068 26.0%   
CASH FLOW
From Operations Rs m9,3046,574 141.5%  
From Investments Rs m-3,105-7,124 43.6%  
From Financial Activity Rs m-1,9595,432 -36.1%  
Net Cashflow Rs m4,2401,992 212.8%  

Share Holding

Indian Promoters % 74.1 48.3 153.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 6.9 42.0%  
FIIs % 9.1 34.4 26.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.5 132.4%  
Shareholders   49,328 56,727 87.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  CADILA HEALTHCARE  SUVEN LIFE  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue to Fall, IT Sector Growth Projections, and Top Stocks in Action(Pre-Open)

On Wednesday, share markets in India opened in green but ended on a weak note. The BSE Sensex closed lower by 71 points to end the day at 33,704.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 20, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS